TOKYO -- A Japanese startup is poised to become the first in the world to seek government approval for a therapy derived from human induced pluripotent stem (iPS) cells, Nikkei has learned, with a less invasive alternative for treating heart disease.
Osaka University-affiliated Cuorips has developed a cardiac tissue sheet using iPS cells, which can be grafted onto the hearts of patients suffering from coronary artery disease. It plans to file an application to make and sell these sheets with Japan's Ministry of Health, Labor and Welfare as early as June.
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
